The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA)
March 29, 2014—AccessClosure Inc. (Santa Clara, CA) announced the commercial launch of its Mynx Ace vascular closure device at ACC.14: the 63rd annual scientific session of the American College of Cardiology being held March 29–31, in Washington, DC.
March 30, 2014—Medtronic, Inc. (Minneapolis, MN) announced to the presentation of an analysis of 6-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry. The data were presented during a late-breaking clinical trial session at ACC.14, the 63rd scientific sessions of the American College of Cardiology (ACC) in Washington, DC.
March 29, 2014—Medtronic, Inc. (Minneapolis, MN) announced that the full results of the SYMPLICITY HTN-3 clinical trial were presented in a late-breaking session at the ACC.14: 63rd annual scientific sessions of the American College of Cardiology and published simultaneously online ahead of print in The New England Journal of Medicine. SYMPLICITY HTN-3 is a blinded, randomized, sham-controlled study of renal denervation for treatment-resistant hypertension. ACC.14 is being held on March 29–31, in Washington, DC.
March 24, 2014—The Society of Interventional Radiology (SIR) announced findings from a study demonstrating that 72% of men with benign prostatic hyperplasia who were treated via prostate artery embolization (PAE) continued to show symptom improvement at 3-year follow-up. Minimally invasive, image-guided PAE is a transcatheter procedure that releases microscopic beads into the artery where they lodge and temporarily block blood flow to the prostate, causing it to shrink. The study was presented at SIR’s 39th Annual Scientific Meeting in San Diego, California, and is available online as Abstract 108 at www.sirmeeting.org.
March 24, 2014—The Society of Interventional Radiology (SIR) announced that yttrium-90 (Y-90) radioembolization of the artery that supplies the liver shows promise in treating breast cancer that has spread to the liver when no other treatment options remain. In this procedure, microbeads are administered into the blood stream, float out to the smaller vessels that feed the tumor, and emit cancer-killing radiation from inside the tumor. Because Y-90 is targeted directly to the tumor, radiation damage to healthy surrounding tissues is minimized. The study was presented at the SIR’s 39th annual scientific meeting in San Diego, California, and is available as Abstract 192 at www.sirmeeting.org.
April 7, 2014—Alvimedica Medical Technologies (Catalca, Turkey) announced the launch of the Cre8 BTK drug-eluting stent (DES), a polymer-free device for the treatment of below-the-knee (BTK) lesions, as part of the company s introduction of its endovascular device portfolio. The device was launched at the Charing Cross international symposium in London, United Kingdom, for use in the European Union and other markets that recognize CE Mark approval, which the company received in July 2013.
April 5, 2014—Twelve-month results from the IN.PACT SFA trial studying the In.Pact Admiral drug-coated balloon (DCB) (Medtronic, Inc., Minneapolis, MN) were presented at the Charing Cross international symposium in London. Principal investigator Gunnar Tepe, MD, presented the data, which showed that patients with peripheral artery disease in the superficial femoral artery (SFA) who were treated with the In.Pact Admiral device experienced significantly better outcomes at 12 months after treatment compared to those treated with standard percutaneous transluminal angioplasty (PTA).
March 27, 2014—CryoLife, Inc. (Kennesaw, GA) announced that it has acquired the exclusive worldwide distribution rights for the ProCol vascular bioprosthesis from Hancock Jaffe Laboratories, Inc. (Irvine, CA), and it has the right to acquire the ProCol product line from Hancock Jaffe, beginning 24 months after execution of the agreement.
BioCardia announced receipt of the CE mark for its Morph AccessPro steerable introducer, designed for easier navigation through the vasculature during delivery of biotherapeutics and medical devices.
Por séptimo año consecutivo se ha celebrado el Curso de Neoplasias Digestivas en el Auditorio Reina Sofía de HM Universitario Sanchinarro. El Dr. Carlos Mascías, director médico de dicho hospital, presentó la jornada y calificó como “un orgullo el hecho de que ya vayamos por la séptima edición de este curso, y que año tras año consigamos que acuda más gente interesada en el tratamiento personalizado del cáncer, en la innovación y en la investigación”. El Dr. Mascías también agradeció al Dr. Manuel Hidalgo, director del Centro Integral Oncológico Clara Campal (CIOCC), al Dr. Antonio Cubillo, coordinador de la Unidad de Tumores Digestivos de HM Universitario Sanchinarro, y a todos los integrantes del servicio de Oncología Médica, la labor que realizan y por la cual el CIOCC ha llegado a situarse al mismo nivel que los mejores hospitales de España en Oncología.
La hidratación se ha convertido en un factor de primer orden y de reconocida importancia dentro de la nutrición y del campo de la salud en general, a pesar de ser un área de estudio científico relativamente novedosa. Así lo demuestra el amplio número de investigaciones que se están llevando a cabo en este sentido y la gran atención que los científicos y expertos en nutrición muestran al respecto.
Los planes de adelgazamiento que prometen grandes pérdidas de peso en poco tiempo, además de no ser efectivos, son peligrosos, ya que suelen excluir grupos alimenticios enteros, pudiendo generar carencias nutricionales importantes. Además, aunque sí se consigue un adelgazamiento inicial, el peso se recupera rápidamente e incluso algunos kilos más de propina debido al temido ‘efecto rebote’.
La llamada comida feliz es una tendencia que está de moda. Siempre hemos sabido que comer productos como el chocolate nos hacía sentir mejor, pero la realidad es que sí hay un motivo científico por el que determinados alimentos nos provocan un placer instantáneo, y es porque estimulan la segregación de endorfinas y serotonina, llamadas hormonas de la felicidad, la alegría o el placer. ¿Cuáles son los alimentos que podemos etiquetar dentro de comida feliz?
Medtronic announced that the SYMPLICITY HTN-3 clinical trial, the first and only blinded, randomised, sham controlled study of renal denervation for treatment-resistant hypertension, met its primary safety endpoint but did not meet its primary or secondary efficacy endpoints. The results were presented in a late-breaking session at the 63rd Scientific Sessions of the American College of Cardiology (ACC) and published simultaneously in The New England Journal of Medicine.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos